USANA Health Sciences (NASDAQ:USNA) was upgraded by Zacks from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Market Beat Ratings reports. The brokerage presently has a $167.00 target price on the stock. Zacks‘s target price would indicate a potential upside of 15.05% from the stock’s previous close.
According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system.“
In related news, insider Deborah Woo sold 3,656 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $132.06, for a total transaction of $482,811.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Myron W. Wentz sold 7,000 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $138.28, for a total transaction of $967,960.00. The disclosure for this sale can be found here.
A number of other analysts have also recently weighed in on the company. DA Davidson cut USANA Health Sciences from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $165.00 to $180.00 in a research report on Thursday, August 6th. Canaccord Genuity reissued a “hold” rating and set a $136.00 price target on shares of USANA Health Sciences in a report on Wednesday, August 5th. Finally, Pivotal Research raised USANA Health Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $135.00 to $200.00 in a report on Wednesday, August 5th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $170.75.
Shares of USANA Health Sciences (NASDAQ:USNA) traded up 2.81% during mid-day trading on Tuesday, hitting $145.16. The stock had a trading volume of 181,758 shares. The firm has a 50 day moving average price of $142.06 and a 200 day moving average price of $125.04. USANA Health Sciences has a 52-week low of $69.76 and a 52-week high of $176.88. The firm has a market cap of $1.86 billion and a PE ratio of 22.13.
USANA Health Sciences (NASDAQ:USNA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.60 by $0.32. During the same quarter in the prior year, the business earned $1.36 earnings per share. The business earned $233.20 million during the quarter, compared to analyst estimates of $211.86 million. The firm’s quarterly revenue was up 23.8% on a year-over-year basis. Equities analysts predict that USANA Health Sciences will post $7.18 EPS for the current year.
USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company has operations in 19 markets across the world, where it distributes and sells its products by way of direct selling. The Company operates as a direct selling company and reports revenue in two geographic regions: Americas and Europe and Asia Pacific, which is further divided into three sub-regions; Southeast Asia Pacific, Greater China, and North Asia. Americas and Europe includes the United States, Canada, Mexico, Colombia, the United Kingdom, France, Belgium, and the Netherlands. Southeast Asia Pacific includes Australia, New Zealand, Singapore, Malaysia, the Philippines, and Thailand; Greater China includes Hong Kong, Taiwan and China; and North Asia includes Japan and South Korea.
Source: http://www.dakotafinancialnews.com/usana-health-sciences-upgraded-at-zacks-usna/385160/
Be the first to comment on "USANA Health Sciences Upgraded at Zacks"